Deerfield Management Company L.P. Series C Has $1.35 Million Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Deerfield Management Company L.P. Series C raised its position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 297.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,742 shares of the company's stock after buying an additional 22,251 shares during the quarter. Deerfield Management Company L.P. Series C owned about 0.16% of USANA Health Sciences worth $1,346,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quest Partners LLC bought a new stake in shares of USANA Health Sciences during the 4th quarter worth $66,000. CWM LLC boosted its stake in shares of USANA Health Sciences by 21.8% in the 1st quarter. CWM LLC now owns 1,543 shares of the company's stock valued at $75,000 after purchasing an additional 276 shares in the last quarter. BOKF NA boosted its stake in shares of USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company's stock valued at $133,000 after purchasing an additional 2,031 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of USANA Health Sciences during the 4th quarter valued at approximately $266,000. Finally, Price T Rowe Associates Inc. MD increased its position in USANA Health Sciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company's stock worth $284,000 after purchasing an additional 494 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on USNA shares. StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, July 24th. DA Davidson cut their price objective on USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating on the stock in a report on Thursday, July 25th.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock traded up $1.32 on Thursday, hitting $37.83. The stock had a trading volume of 95,292 shares, compared to its average volume of 79,988. The stock has a 50 day moving average of $40.18 and a 200 day moving average of $44.17. The firm has a market capitalization of $720.66 million, a P/E ratio of 11.79, a PEG ratio of 1.27 and a beta of 0.90. USANA Health Sciences, Inc. has a twelve month low of $36.05 and a twelve month high of $59.85.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.11). The business had revenue of $212.87 million during the quarter, compared to analyst estimates of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same quarter last year, the company posted $0.89 earnings per share. Equities analysts expect that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the company's stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now owns 2,503 shares of the company's stock, valued at $111,208.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders sold a total of 7,940 shares of company stock valued at $311,670 in the last three months. Insiders own 0.33% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.